GASTRIC AND ESOPHAGEAL CANCER DRUGS MARKET ANALYSIS

Regional Analysis

Gastric and Esophageal Cancer Drugs Market- Regional Analysis

On the basis of region, the global gastric and esophageal cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is expected to be the leading region in the gastric and esophageal cancer drugs market during the forecast period, owing to the high prevalence of esophageal cancer in this region. For instance, the American Cancer Society estimated that about 17,650 new esophageal cancer cases in the U.S. will be diagnosed (13,750 in men and 3,900 in women) by 2019. Moreover, mergers and acquisition activities by key players in this region are expected to propel market growth during the forecast period. For instance, in December 2018, GlaxoSmithKline plc announced the acquisition of TESARO Inc, an oncology-focused company based in Massachusetts, U.S. This acquisition is expected to strengthen GSK's pharmaceutical business by accelerating GSK's pipeline and commercial capability in oncology.

Key players in Europe are focused on various business strategies such as acquisitions and mergers, which in turn boosts the growth of the market. For instance, in September 2018, Boehringer Ingelheim acquired all shares of ViraTherapeutics, an Austria-based biopharmaceutical company specializing in the development of oncolytic viral therapies. The total transaction value for this acquisition was US$ 240.52 million. This acquisition strengthened Boehringer Ingelheim's commitment to research and development for viral-based immuno-oncology treatment.